← Eichor
Study identifier: NCT07263438 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial

Condition: Glioblastoma · Recurrence Tumor  ·  Sponsor: Centre Hospitalier Universitaire Vaudois

PhasePhase 2
Planned participants59
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. Eligible patients will be assigned to two cohorts depending on whether there is a medical indication for a neurosurgical resection from first recurrent tumor or not. The aim of the cohort 1 (patients without indication for surgery) is to analyze the clinical efficacy of this triple combination in recurrent glioblastoma. 48 patients will be registered. The aim of cohort 2 (patients with indication for surgery) is to confirm the level of trimipramine that can be achieved in the tumor tissue and cerebrospinal fluid collected during surgery. At least 5 patients will be registered. All patients will receive the combination treatment (trimipramine and atezolizumab associated with bevacizumab) for a maximum period of 2 years from registration. The treatment schedule is slightly different for the 2 cohorts because of the neurosurgical resection foreseen for cohort 2 and the requirement to start bevacizumab only after the surgery. After the end of treatment, all patients will be followed up for safety during 90 days from first treatment administration and then up to 3 years from registration.

This description comes directly from the study's public registry record.

Talk to the study team

Andreas Hottinger, MD, PhD  ·  0041 79 556 52 71  ·  andreas.hottinger@chuv.ch

Stéphanie Viguet-Carrin, PhD  ·  0041 79 556 45 63  ·  stephanie.viguet-carrin@chuv.ch

Always discuss trial participation with your own doctor first.

Locations (7)

Universitätsspital BaselBasel, Basel, SwitzerlandRecruiting
Kantonsspital AarauAarau, Canton of Aargau, SwitzerlandRecruiting
Bern InselspitalBern, Canton of Bern, SwitzerlandRecruiting
HFR Fribourg - Hôpital cantonalFribourg, Canton of Fribourg, SwitzerlandRecruiting
Luzerner KantonsspitalLucerne, Canton of Lucerne, SwitzerlandRecruiting
Centre Hospitalier Universitaire VaudoisLausanne, Canton of Vaud, SwitzerlandRecruiting
Universitätsspital ZürichZurich, Canton of Zurich, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07263438